Radiotherapy Biomarkers
Radiotherapy Biomarkers - Related Videos
11:38
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
0 Views •
Cited by 49 •
2014
The current priority in breast cancer radiotherapy is to reduce cardiac doses without compromising target tissue coverage. The voluntary breath-hold technique described here is a simple, inexpensive solution to this problem and capable of being instituted widely without the need for specialized equipment.
11:24
Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
0 Views •
Cited by 10 •
2011
Brain tumor patients routinely undergo cranial radiotherapy, and while beneficial, this treatment often results in debilitating cognitive dysfunction. This serious unresolved problem has at present, no clinical recourse, and has driven our efforts to devise stem cell based therapies for the recovery of radiation-induced cognitive decrements.
08:02
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
0 Views •
Cited by 9 •
2012
The purpose of this article is to describe the use of an orthotopic glioblastoma model for chemoradiation studies. This article will go though cell processing, implanting, and radiotherapy of the mouse using an intracranial model.
08:29
Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
0 Views •
Cited by 29 •
2012
We describe a rat model of post traumatic stress disorder (PTSD) that reveals the persistent alterations in neuroendocrine function and the delayed long-term, exaggerated fear response, characteristic of PTSD patients. The animal model and methods described here are useful for correlating biomarkers in brain nuclei, which are mechanistic but cannot be measured in patients, with biomarkers in peripheral white blood cells, which can.
08:28
An Overview of bGDGT Biomarker Analysis for Paleoclimatology
0 Views •
2023
Source: Laboratory of Jeff Salacup - University of Massachusetts Amherst Throughout this series of videos, natural samples were extracted and purified in search of organic compounds, called biomarkers, that can relate information on climates and environments of the past. One of the samples analyzed was sediment. Sediments accumulate over geologic time in basins, depressions in the Earth into which sediment flows through the action of fluid (water or air), movement, and gravity. Two main types...
FAQs
Tumor hypoxia can signal reduced oxygen availability within a tumor, a condition that influences how cells respond to radiation. By capturing this biological feature, a radiotherapy biomarker may help distinguish tumors with different expected radiosensitivity. That information can support treatment selection and response prediction, while highlighting why tumors receiving the same radiation dose may behave differently.
Signals related to DNA damage and repair help connect radiation exposure with the tumor’s ability to maintain or restore its genetic material. Cell-cycle regulation adds another layer because the growth state of cells can influence radiosensitivity. Together, these features can explain variation in treatment response and provide mechanistic context for comparing expected benefits among patients.
Imaging-based signals provide a different view from molecular or biological measurements because they can characterize features visible within the tumor. In radiotherapy research, this distinction is useful when investigators assess treatment response, plan radiation, or evaluate risk. Comparing these biomarker categories helps clarify which tumor or tissue characteristics are most informative for a particular clinical purpose.
Immune activity is relevant because it represents a biological process that may influence how tumors respond during radiotherapy. Measuring this feature can help researchers investigate which patients might benefit from combining radiation with immunotherapy. It also extends biomarker research beyond radiation sensitivity alone, linking treatment response prediction with the search for more individualized combination strategies.
Patient selection uses biomarker information to identify differences in expected treatment response or toxicity risk during treatment planning. In cancer research, this can help distinguish patients who may be more likely to benefit from a radiation-based approach or from an added treatment. The objective is to connect tumor or tissue biology with a more individualized treatment decision.
Treatment monitoring applies biomarker information over the course of care rather than using it only for initial prediction. In cancer research, this approach can help evaluate whether the tumor is responding and whether normal tissue may be developing treatment-related risk. It therefore adds a time-dependent perspective to patient assessment and may provide information for treatment planning.
Radiotherapy biomarkers may contribute to dose planning by indicating biological differences among tumors or tissues. Information about hypoxia, DNA repair, cell-cycle regulation, or immune activity can help researchers examine whether planned radiation exposure fits the expected biology. Their role is to add biological context to planning and may support more personalized approaches to radiation treatment.
Biomarkers of normal-tissue response are important for risk assessment because effective tumor treatment can still produce unwanted side effects. Identifying biological signals associated with toxicity may help researchers evaluate which patients face greater treatment-related risk. This complements tumor-response biomarkers, which focus on benefit, and supports a more balanced approach to personalized radiotherapy.